Yoo‐Joung Ko

PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy

Sharlene Gill, Yoo‐Joung Ko, C. Cripps et al. · Journal of Clinical Oncology · 2016 · 291 citations

Medicine, Oncology, Pharmacotherapy +13

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

Daniel J. Renouf, Jonathan M. Loree, Jennifer J. Knox et al. · Nature Communications · 2022 · 139 citations · Full text

Medicine, Oncology, Pharmacology +17

Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study

Yoo‐Joung Ko, C. Canil, Som D. Mukherjee et al. · The Lancet Oncology · 2013 · 138 citations

Pharmacy, Oncology, Pharmacology +17

A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial

Derek J. Jonker, Patricia A. Tang, Hagen F. Kennecke et al. · Clinical Colorectal Cancer · 2018 · 58 citations

Medicine, Oncology, Pharmacotherapy +11

PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT).

Sharlene Gill, Yoo‐Joung Ko, M. Christine Cripps et al. · Journal of Clinical Oncology · 2014 · 49 citations

Medicine, Oncology, Pharmacology +16